Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr34.55
kr0.22(1.39%)
At close: 4:00 PM EST
kr34.55
kr0.22(1.39%)
Day’s Range― - ―
52-Week Rangekr16.84 - kr43.40
Previous CloseN/A
Volume4.04K
Average Volume (3M)101.19K
Market Cap
kr750.82M
Enterprise Valuekr388.31
Total Cash (Recent Filing)kr386.20M
Total Debt (Recent Filing)kr7.00M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Oct 22, 2026EPS Estimate
-1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.10
Shares Outstanding35,127,056
10 Day Avg. Volume22,969
30 Day Avg. Volume101,192
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.03
Revenue Forecast (FY)kr25.60M
Bulls Say, Bears Say
Bulls Say
Positive Operating And Free Cash FlowTrailing‑twelve‑month operating and free cash flow turning meaningfully positive (~SEK 117M) marks a durable improvement versus multi‑year cash deficits. Positive cash generation increases financial optionality to fund development, pursue partnerships, and reduces near‑term reliance on equity raises if maintained.
Very Low Leverage And Positive EquityA debt‑to‑equity of ~0.02 and positive equity materially reduces solvency risk and interest burden, giving Orexo structural financial flexibility. This stronger capital structure supports sustained R&D and partnership negotiations and lowers bankruptcy risk versus peers with higher leverage.
Strong IP And AmorphOX Platform ExclusivityLong patent run‑dates (OX640 to 2044; GLP‑1 extensions to ~2047) and the AmorphOX thermostability platform represent durable competitive assets. Extended exclusivity and platform utility underpin potential licensing, premium pricing and partner interest across vaccines and biologics, supporting long‑term value creation.
Bears Say
Sharp Revenue ContractionA >50% TTM revenue decline and persistently negative gross, operating and net margins signal the core commercial business is not covering fixed costs. Structural revenue weakness undermines self‑funding of pipeline activities, weakens negotiating leverage with partners, and makes long‑term recovery contingent on new product launches or deals.
Large Quarterly Losses And Cash OutflowsSubstantial quarter‑level losses and heavy cash outflows reduce runway and force management to secure financing or accelerate partnerships. Even with TTM cash improvement, episodic large burns related to development and settlements can deplete reserves, pressure capital allocation, and increase dilution risk before structural revenue recovery.
Protracted DOJ Investigation And Legal RiskA multi‑year unresolved DOJ matter is a persistent structural overhang: uncertain settlement size/timing, elevated legal costs and partial insurance coverage can constrain cash, hinder partner and investor confidence, and limit access to attractive financing until materially resolved or insured exposures are clarified.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr16.84 and its highest was kr43.40 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr750.82M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 97 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -kr1.6 earnings per share for the quarter, the consensus estimate of -kr1.6 by kr0.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -1.4.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr1.6 in its last earnings report, expectations of -kr1.6. Following the earnings report the stock price went down -16.279%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―